title: Molecular markers for colon diagnosis, prognosis and targeted therapy.
abstract: Colorectal adenocarcinoma (CRC), the second leading cancer-related death in the United States, remains a global public health issue. Sporadic CRC is considered the result of sequential mucosal changes from normal colonic mucosa to adenocarcinoma. Efforts in understanding the molecular pathways leading to CRC tumorigenesis may lead to identifying novel, individually tailored therapeutic targets for patients. In this review, we focus on well-published prognostic and predictive markers in CRC and examine their role in clinical practice.
authors.affiliation: Department of Surgery, Oregon Health & Science University, Portland, Oregon.
authors.forename: Daniel O
authors.initials: DO
authors.lastname: Herzig
authors.forename: Vassiliki L
authors.initials: VL
authors.lastname: Tsikitis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D058990:Molecular Targeted Therapy; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: BRAF V600E; KRAS; MSI; PI3K; TP53